drugset / Trial / NCT00938184

Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects

NCT00938184

Phase 1 Completed 18 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelOther

Summary

The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.

Timeline

Start
2009-07-14
Primary completion
2009-09-02
Completion
2009-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 12.5 mg Oral
Subject Paroxetine Small molecule 25 mg Oral
Subject Paroxetine Small molecule 50 mg Oral

Indications